: Moderna set to join S&P 500, stock rallies 8%


Moderna Inc., a biotechnology company catapulted to fame after it produced a highly effective COVID-19 vaccine, is set to join the S&P 500 index, a seal of approval that will put the stock in countless index-tracking and actively managed funds and retirement accounts.

Shares of Moderna MRNA, +5.28% rallied 8% in the extended session Thursday after the announcement. The stock has gained 149% this year, compared with gains of 16% for the S&P 500 SPX, -0.33% in the same period.

Moderna will replace Alexion Pharmaceuticals Inc. ALXN, -3.27% at the opening on July 21, S&P Dow Jones Indices, the index manager, said in a statement.

Boston-area Moderna was a scrappy biotech startup relatively unknown before its successful COVID-19 vaccine, approved last year in the U.S. on an emergency basis for adults. The shot, like the one from Pfizer Inc. PFE, +0.35%, uses messenger-RNA technology. Both vaccines have shown efficacy of more than 90%.

AstraZeneca Plc. AZN, -4.75%, which also has developed a COVID-19 vaccine alongside Oxford University, is buying Alexion and the the $39 billion deal is expected to close soon. The companies announced the deal in December.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleDow ekes out gain as stocks finish mostly lower
Next articleMutual Funds Weekly: These money and investing tips can help you read the market’s signs and stay on your path


Please enter your comment!
Please enter your name here